Antigen News and Research

RSS

USA's largest ever prostate cancer screening program shows high compliance and consistent results

Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the urology journal BJU International .

15 Dec 2008

Researchers solve failed vaccine mystery

Research led by Johns Hopkins Children's Center scientists has figured out why a respiratory syncytial virus vaccine used in 1966 to inoculate children against the infection instead caused severe respiratory disease and effectively stopped efforts to make a better one.

15 Dec 2008

Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men

15 Dec 2008

Vaxfectin-formulated H5N1 pandemic influenza achieves T-cell responses and cross-clade reactivity in humans

Vical Incorporated has announced that the company's Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial.

11 Dec 2008

Mathematical models of adaptive immunity

More than five million people die every year from infectious diseases, despite the availability of numerous antibiotics and vaccines. The discovery of penicillin to treat bacterial infections, along with the development of vaccines for previously incurable virus diseases such as polio and smallpox, achieved great reductions in mortality during the mid-20th century.

11 Dec 2008

Genetic links found between type 1 diabetes and celiac disease

Type 1 (juvenile) diabetes and celiac disease appear to share a common genetic origin, scientists at the University of Cambridge and Barts and The London School of Medicine and Dentistry, have confirmed.

10 Dec 2008

Scans show immune cells intercepting parasites

Researchers may have identified one of the body's earliest responses to a group of parasites that causes illness in developing nations.

10 Dec 2008

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor, Inc. presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb 5574, a monoclonal antibody engineered using Xencor's XmAb Fc technologies that targets the antigen CD19.

10 Dec 2008

Vaccine against malaria could be ready in 5 years

Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome.

9 Dec 2008

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient's blood supply is as safe as a standard cord blood transplant, researchers reported at the 50th Annual Meeting of the American Society of Hematology.

8 Dec 2008

Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM).

8 Dec 2008

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Effects of stem cell source and patient age on stem cell transplantation outcomes

Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes were explored at a press conference on Sunday, December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

New insights into development of the human immune system

A UCSF study has found that a surprisingly high number of maternal cells enters the fetus during pregnancy, prompting the generation of special immune cells in the fetus that suppress a response against the mother.

5 Dec 2008

Degarelix prostate cancer drug makes testosterone levels fall dramatically and quickly

More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.

3 Dec 2008

New insight into adhesion and migration of dendritic cells could lead to novel cancer treatments

Our immune system plays an essential role in protecting us from diseases, but how does it do this exactly?

1 Dec 2008

EpiVax receives grant for $390,000 to optimize HIV vaccine delivery

EpiVax, Inc., a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine.

26 Nov 2008

Immune cells reveal fancy footwork

Our immune system plays an essential role in protecting us from diseases, but how does it do this exactly?

25 Nov 2008

Scientists present 'moving' theory behind bacterial decision-making

Biochemists at North Carolina State University have answered a fundamental question of how important bacterial proteins make life-and-death decisions that allow them to function, a finding that could provide a new target for drugs to disrupt bacterial decision-making processes and related diseases.

24 Nov 2008

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

Antigen News and Research

USA's largest ever prostate cancer screening program shows high compliance and consistent results

Researchers solve failed vaccine mystery

Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men

Vaxfectin-formulated H5N1 pandemic influenza achieves T-cell responses and cross-clade reactivity in humans

Mathematical models of adaptive immunity

Genetic links found between type 1 diabetes and celiac disease

Scans show immune cells intercepting parasites

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Vaccine against malaria could be ready in 5 years

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Effects of stem cell source and patient age on stem cell transplantation outcomes

New insights into development of the human immune system

Degarelix prostate cancer drug makes testosterone levels fall dramatically and quickly

New insight into adhesion and migration of dendritic cells could lead to novel cancer treatments

EpiVax receives grant for $390,000 to optimize HIV vaccine delivery

Immune cells reveal fancy footwork

Scientists present 'moving' theory behind bacterial decision-making

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics